(CBRE) CBRE - Overview
Stock: Advisory, Facilities, Investments, Development
| Risk 5d forecast | |
|---|---|
| Volatility | 41.8% |
| Relative Tail Risk | -14.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.16 |
| Alpha | -11.25 |
| Character TTM | |
|---|---|
| Beta | 0.976 |
| Beta Downside | 1.092 |
| Drawdowns 3y | |
|---|---|
| Max DD | 26.04% |
| CAGR/Max DD | 0.78 |
EPS (Earnings per Share)
Revenue
Description: CBRE CBRE January 29, 2026
CBRE Group, Inc. (NYSE: CBRE) is the world’s largest commercial real-estate services firm, operating three core segments: Advisory Services (leasing, sales, financing, property management, and valuation), Global Workplace Solutions (facilities and project management under the Turner & Townsend brand), and Real-Estate Investments (institutional investment management and development via Trammell Crow and Telford Homes). The company, founded in 1906 and headquartered in Dallas, Texas, serves owners, occupiers, and investors across office, industrial, retail, data-center, and specialty property types in the U.S., U.K., and globally.
Recent performance metrics (FY 2023) show total revenue of $27.5 billion, a 6 % year-over-year increase driven primarily by higher advisory fees and a rebound in industrial leasing, while adjusted EBITDA reached $3.3 billion (≈12 % margin). The U.S. office vacancy rate stabilized at 15 % in Q4 2023 after a two-year rise, whereas industrial vacancy fell to 4 %-the lowest in a decade-reflecting sustained e-commerce and logistics demand. A key macro driver is the Federal Reserve’s policy rate, which sits near 5.5 % and influences both commercial-mortgage financing costs and institutional capital allocation.
Assuming CBRE can maintain its diversified service mix and capitalize on the ongoing industrial-space shortage, the firm’s earnings outlook remains positive, but it remains vulnerable to a prolonged office-space downturn or a sharp increase in financing rates that could suppress investment activity. Disconfirming evidence would include a sustained acceleration in office vacancy above 18 % or a marked contraction in institutional capital commitments.
For a deeper quantitative dive into CBRE’s valuation sensitivities and scenario analysis, you might explore the data tools on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 1.16b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -2.26 > 1.0 |
| NWC/Revenue: 2.88% < 20% (prev 1.91%; Δ 0.97% < -1%) |
| CFO/TA 0.05 > 3% & CFO 1.56b > Net Income 1.16b |
| Net Debt (1.40b) to EBITDA (2.49b): 0.56 < 3 |
| Current Ratio: 1.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (299.9m) vs 12m ago -2.74% < -2% |
| Gross Margin: 35.88% > 18% (prev 0.20%; Δ 3568 % > 0.5%) |
| Asset Turnover: 146.8% > 50% (prev 146.7%; Δ 0.08% > 0%) |
| Interest Coverage Ratio: 9.51 > 6 (EBITDA TTM 2.49b / Interest Expense TTM 185.0m) |
Altman Z'' 2.16
| A: 0.04 (Total Current Assets 13.49b - Total Current Liabilities 12.32b) / Total Assets 30.88b |
| B: 0.32 (Retained Earnings 9.92b / Total Assets 30.88b) |
| C: 0.06 (EBIT TTM 1.76b / Avg Total Assets 27.63b) |
| D: 0.42 (Book Value of Equity 8.88b / Total Liabilities 21.25b) |
| Altman-Z'' Score: 2.16 = BBB |
Beneish M -3.47
| DSRI: 0.93 (Receivables 8.49b/8.10b, Revenue 40.55b/35.77b) |
| GMI: 0.54 (GM 35.88% / 19.55%) |
| AQI: 0.92 (AQ_t 0.46 / AQ_t-1 0.50) |
| SGI: 1.13 (Revenue 40.55b / 35.77b) |
| TATA: -0.01 (NI 1.16b - CFO 1.56b) / TA 30.88b) |
| Beneish M-Score: -3.47 (Cap -4..+1) = AA |
What is the price of CBRE shares?
Over the past week, the price has changed by +4.09%, over one month by -13.61%, over three months by -6.99% and over the past year by +6.61%.
Is CBRE a buy, sell or hold?
- StrongBuy: 5
- Buy: 4
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CBRE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 181.9 | 23.7% |
| Analysts Target Price | 181.9 | 23.7% |
CBRE Fundamental Data Overview February 20, 2026
P/E Forward = 19.3424
P/S = 1.0949
P/B = 4.7703
P/EG = 0.7131
Revenue TTM = 40.55b USD
EBIT TTM = 1.76b USD
EBITDA TTM = 2.49b USD
Long Term Debt = 5.05b USD (from longTermDebt, last quarter)
Short Term Debt = 1.14b USD (from shortTermDebt, last quarter)
Debt = 3.26b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.40b USD (from netDebt column, last quarter)
Enterprise Value = 45.79b USD (44.40b + Debt 3.26b - CCE 1.86b)
Interest Coverage Ratio = 9.51 (Ebit TTM 1.76b / Interest Expense TTM 185.0m)
EV/FCF = 38.39x (Enterprise Value 45.79b / FCF TTM 1.19b)
FCF Yield = 2.61% (FCF TTM 1.19b / Enterprise Value 45.79b)
FCF Margin = 2.94% (FCF TTM 1.19b / Revenue TTM 40.55b)
Net Margin = 2.85% (Net Income TTM 1.16b / Revenue TTM 40.55b)
Gross Margin = 35.88% ((Revenue TTM 40.55b - Cost of Revenue TTM 26.00b) / Revenue TTM)
Gross Margin QoQ = 15.29% (prev 19.40%)
Tobins Q-Ratio = 1.48 (Enterprise Value 45.79b / Total Assets 30.88b)
Interest Expense / Debt = 0.83% (Interest Expense 27.0m / Debt 3.26b)
Taxrate = 20.21% (114.0m / 564.0m)
NOPAT = 1.40b (EBIT 1.76b * (1 - 20.21%))
Current Ratio = 1.09 (Total Current Assets 13.49b / Total Current Liabilities 12.32b)
Debt / Equity = 0.37 (Debt 3.26b / totalStockholderEquity, last quarter 8.88b)
Debt / EBITDA = 0.56 (Net Debt 1.40b / EBITDA 2.49b)
Debt / FCF = 1.17 (Net Debt 1.40b / FCF TTM 1.19b)
Total Stockholder Equity = 8.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.19% (Net Income 1.16b / Total Assets 30.88b)
RoE = 13.63% (Net Income TTM 1.16b / Total Stockholder Equity 8.49b)
RoCE = 12.99% (EBIT 1.76b / Capital Employed (Equity 8.49b + L.T.Debt 5.05b))
RoIC = 8.98% (NOPAT 1.40b / Invested Capital 15.62b)
WACC = 8.90% (E(44.40b)/V(47.66b) * Re(9.51%) + D(3.26b)/V(47.66b) * Rd(0.83%) * (1-Tc(0.20)))
Discount Rate = 9.51% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.41%
[DCF Debug] Terminal Value 75.93% ; FCFF base≈1.31b ; Y1≈1.41b ; Y5≈1.70b
Fair Price DCF = 80.36 (EV 25.12b - Net Debt 1.40b = Equity 23.72b / Shares 295.2m; r=8.90% [WACC]; 5y FCF grow 7.89% → 2.90% )
EPS Correlation: 23.44 | EPS CAGR: 19.72% | SUE: 0.89 | # QB: 6
Revenue Correlation: 88.47 | Revenue CAGR: 13.08% | SUE: -1.47 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.12 | Chg30d=+0.031 | Revisions Net=+1 | Analysts=5
EPS current Year (2026-12-31): EPS=7.50 | Chg30d=+0.058 | Revisions Net=+2 | Growth EPS=+17.6% | Growth Revenue=+14.3%
EPS next Year (2027-12-31): EPS=8.80 | Chg30d=+0.125 | Revisions Net=+2 | Growth EPS=+17.3% | Growth Revenue=+8.5%